Savara, Inc. · NASDAQ:SVRA
Savara — Investor Presentation (June 2023)
32 slides from Savara's investor presentation, June 2023
Slide 1: Corporate Overview
Corporate Overview Developing New Therapies for Rare Respiratory Diseases June 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “w
Slide 3: Executive Leadership Team
Executive Leadership Team Matthew Pauls, J.D., M.B.A. Dave Lowrance Rob Lutz, M.B.A. Ray Pratt, M.D. FACP Chair & Chief Executive Officer Chief Financial & Administrative Officer Chief Operating Officer Chief Medical Officer Peter Clarke, Ph.D. Scott Wilhoit EVP, Global Technical Operations EVP, Glo
Slide 4: Pursuing Transformative Therapies for Rare Respiratory Diseases
Pursuing Focused on single Phase 3 program: molgramostim nebulizer Transformative solution (molgramostim) in autoimmune pulmonary alveolar proteinosis (aPAP) Therapies for Rare • Recombinant form of human granulocyte-macrophage colony-stimulating Respiratory factor (GM-CSF) Diseases • Favorable effi
Slide 5: Investment Thesis
Investment Thesis The molgramostim in aPAP clinical program has a high probability of success As a novel inhaled biologic, molgramostim has the potential for a long-term, durable revenue stream Significant global commercial opportunity Strong balance sheet – funded through 2025 5 © Savara Inc. All R
Slide 6: Molgramostim Key Highlights
Molgramostim Key Highlights June 2019: IMPALA clinical trial June-Aug. 2022: UK’s results Sept. 2020: IMPALA results Medicines and Healthcare published in New England Products Regulatory Agency § Randomized, double-blind, 24-week, Journal of Medicine (MHRA) awarded placebo-controlled trial molgramos
Slide 7: IMPALA-2 Key Milestones
IMPALA-2 Key Milestones § June 2023: Complete enrollment Company operations § End of 2Q 2024: Top line data readout funded through 2025 (~18-months beyond § Upon a successful trial, Company plans anticipated IMPALA-2 to submit regulatory applications in the US, UK, EU, and Japan top line results) 7
Slide 8: Molgramostim
Molgramostim Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Slide 9: aPAP: A Disease of Alveolar Macrophage Dysfunction
aPAP: A Disease of Alveolar Macrophage Dysfunction Normal Alveolus Alveolus in PAP Alveolar macrophages Need GM-CSF for maturation, Thin surfactant layer Thick surfactant layer expansion, and function (e.g., aPAP PATIENT surfactant clearance) Baseline Alveolar epithelial cells GM-CSF GM-CSF (Week 0)
Slide 10: aPAP is a Rare, Long-Term, Chronic Disease
aPAP is a Rare, Long-Term, Chronic Disease Progressive Shortness of Breath Fatigue, Decreased Exercise Tolerance § Gas exchange in the lungs is impaired and § Fatigue and significantly reduced exercise capacity can patients may experience shortness of breath dramatically impact the simplest of daily
Slide 11: Whole Lung Lavage is a Highly Invasive Procedure
§ Whole lung lavage is an invasive procedure to physically remove excess surfactant from the lungs and requires hospitalization Whole Lung Lavage is a § Performed under general anesthesia by highly experienced Highly Invasive physicians at certain sites Procedure Performed in a Tertiary Center and i
Slide 12: Complications and Short-Comings of Whole Lung Lavage
Complications and Short-Comings of Whole Lung Lavage Potential Complications Short Comings § Rib fracture § Treatment fails to address pathophysiology of disease § Hypoxia § Patients continue to experience § Pneumothorax (collapsed lung) symptomatic deterioration between § Hydrothorax (fluid in pleu
Slide 13: Journey to Diagnosis Can Be Long and Misdiagnosis is Common
Journey to Diagnosis Can Be Long and Misdiagnosis is Common Due to aPAP’s rarity and associated non-specific symptoms, patients are often misdiagnosed with more common pulmonary illnesses (e.g., recurrent pneumonia, chronic bronchitis, COPD, asthma) Diagnostic tests typically conducted to rule-out o
Slide 14: IMPALA Clinical Trial Design
IMPALA Clinical Trial Design = Primary efficacy analyses Period 1: Double-blind Period 2: Open-label n=45 molgramostim 300 µg daily dosing n=45 Screening molgramostim 300 µg intermittent n=47 W 48 placebo BL W8 W 16 W 24 Primary Endpoint* Secondary Endpoints** § Change from baseline in A-aDO2 § 6-mi
Slide 15: IMPALA Trial Did Not Meet the Primary Endpoint
IMPALA Trial Did Not Meet the Primary Endpoint Continuous Once Daily 1 Dosing Regimen (OD) Full Analysis Set (FAS)* Estimated treatment difference of -4.6 mmHg (p=0.17) Revised FAS† Estimated treatment difference of -6.5 mmHG (p=0.025) *Protocol specified analysis (ITT). †Revised analysis excludes 4
Slide 16: IMPALA: DLCO and SGRQ Showed Robust Improvement with Continuous Dosing
IMPALA: DLCO and SGRQ Showed Robust Improvement with Continuous Once Daily (OD) Dosing Regimen Change in Diffusion Capacity for Carbon Monoxide Change in St. George’s Respiratory Questionnaire (DLCO) From Baseline Over 24-weeks1 (FAS) 1 (SGRQ) From Baseline Over 24-weeks1 (FAS) 20 0 Mean Change (% P
Slide 17: IMPALA Open-Label Data Show Sustained Effect
IMPALA Open-Label Data Show Sustained Effect, or Continued Improvement, after Longer-Term Drug Exposure Mean Change in DLCO Mean Change in SGRQ Total Score Use of Whole Lung Lavage During Over Time1 Over Time1 the Blinded Treatment Period1 Blinded Period Open-Label Period 24 Hazard ratio for Time to
Slide 18: Phase 3 IMPALA-2 Trial Design Leverages Key Learnings
Phase 3 IMPALA-2 Trial Design Leverages Key Learnings from IMPALA Period 1: Double-blind Period 2: Open-label n=80 molgramostim 300 µg daily dosing 6-Week Screening DLCO measured at 6 and 3 molgramostim 300 µg daily dosing weeks to baseline to assure stability (change in % n=80 predicted of <15% poi
Slide 19: Clinical Trial Design: IMPALA vs. IMPALA-2
Clinical Trial Design: IMPALA vs. IMPALA-2 IMPALA IMPALA-2 PRIMARY ENDPOINT: Gas Exchange: A-aDO2 PRIMARY ENDPOINT: Gas Exchange: DLCO (surrogate endpoint) (surrogate endpoint) SECONDARY ENDPOINTS: SGRQ Total SECONDARY ENDPOINTS: SGRQ Total (direct patient benefit) 6-minute walk distance (direct pat
Slide 20: Molgramostim Regulatory Landscape
MOLGRAMOSTIM IN aPAP REGULATORY DESIGNATIONS § Orphan Drug Designation, Europe (eligible for 10 years exclusivity) § Orphan Drug Designation, US (eligible for 7 years exclusivity) Molgramostim § Fast Track Designation, US Regulatory § Breakthrough Therapy Designation, US Landscape § Innovation Passp
Slide 21: Commercial Outlook
Commercial Outlook ASAVARA
Slide 22: Significant Global Commercial Opportunity
Significant Global Commercial Opportunity aPAP is a rare chronic disease with high unmet medical need and limited treatment options Potential first and only approved treatment for aPAP globally (well studied, non-invasive, and convenient dosing) Dosing expected to be chronic, providing long-term, du
Slide 23: Published aPAP Epidemiology Studies
Published aPAP Epidemiology Studies DIAGNOSED INCIDENCE IMPLIED IMPLIED REFERENCE METHODOLOGY PREVALENCE PER MILLION US PATIENTS EU PATIENTS PER MILLION Diagnosed Prevalence Registry based in 0.48 6.2 Inoue 2008 Niigata, Japan (0.23-1.00) (3.8-10.3) ~2,058 ~2,325 US insurance claims 6.3 McCarthy 201
Slide 24: US Claims Database Identified ~3,600 Diagnosed aPAP Patients
US Claims Database of 300M+ Lives Identified ~3,600 Diagnosed aPAP Patients* COMPREHENSIVE CLAIMS DATA 300M+ Rx Px Unique Dx Mx § Counted patients with PAP diagnoses codes Patients and no subsequent ~3,600 diagnoses §99% HCPs Diagnosed §98% health systems US aPAP §96% outpatient § Reduced for aPAP P
Slide 25: Current Global aPAP Market has Significant Potential: $1B+
Current Global aPAP Market has Significant Potential: $1B+ § Estimated 5,000-7,000 currently diagnosed patients EU ~2,000-3,000 in US, EU, and Japan § Standard of care is lung lavage US ~2,000-4,000 Japan ~700-800 § No approved therapeutics for chronic treatment § Potential for ultra-rare disease pr
Slide 26: Improving Awareness and Antibody Testing Could Increase Addressable Market 2-4x
Improving aPAP Disease Awareness and Expanding Antibody Testing Could Increase Addressable Market 2-4x § Many aPAP patients are undiagnosed EU • Ultra-rare disease • Current lack of routine testing ~6,000-9,000 • Lack of meaningful treatments § Kitamura (2019) study = aPAP prevalence Japan may be un
Slide 27: Disease Awareness and Antibody Testing Campaigns
Disease Awareness and Antibody Testing Campaigns SAVARA PLANS TO 1. Launch a Disease Awareness and Education Campaign: • US Healthcare Provider (HCP) Website Launch in 2023 — Increase HCP awareness of aPAP, including hallmark symptoms of the disease — Educate HCPs on the need for routine antibody te
Slide 28: Pulmozyme
Pulmozyme® Analog: Pulmozyme® (dornase alpha) § Prototype inhaled biologic § Approved by the FDA in 1993 § No biosimilar available Pulmozyme is a registered trademark of Genentech 28 © Savara Inc. All Rights Reserved.
Slide 29: Financials
Financials
Slide 30: Financial Highlights
§ Well capitalized • ~$115M in cash (as of 3/31/23) • Cash runway extends ~18-months beyond anticipated IMPALA-2 top line results Financial § Strong investor support with coverage from Highlights 6 equity research analysts ANALYST COVERAGE Evercore ISI Liisa Bayko, MSC, MBA H.C. Wainwright Andrew Fe
Slide 31: Investment Thesis
Investment Thesis The molgramostim in aPAP clinical program has a high probability of success As a novel inhaled biologic, molgramostim has the potential for a long-term, durable revenue stream Significant global commercial opportunity Strong balance sheet – funded through 2025 31 © Savara Inc. All
Slide 32: Thank You
Thank You